Skip to content

Visterra, founded in 2008, is a clinical-stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. The company’s proprietary technology platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets. Visterra was acquired by Otsuka Pharmaceutical in 2018.

Latest Press from Visterra

Next